disease the larger the size or proportion of the genome, so were also thought to have high certainty in counseling. Rare CNVs were individually examined to determine their likelihood of having an affected phenotype. RESULTS: There were 970 prenatal CMAs performed. Of these, 58 (6.0%) were categorized as a VUS. The number in each category is shown in Table 1 . Among the 58 VUSs, 33 (56.9%) were associated with a known phenotype, and 56 (96.6%) were associated with a high level of certainty regarding the likelihood of an affected phenotype. CONCLUSION: Most VUSs (96.6% of all VUSs, 99.8% of all CMAs) were associated with a high level of certainty regarding the likelihood of an affected phenotype. Variants of truly uncertain significance are relatively uncommon, and most cases can be categorized as to the potential risk of an affected phenotype and what phenotypes are possible.
OBJECTIVE: Platinum-based chemotherapy, such as carboplatin and more commonly cisplatin damage tiny hair cells in the inner ear that vibrate in response to sound waves. The National Cancer Institute reports at least 50% of children have permanent hearing loss after treatment. The incidence of hearing loss after in utero exposure to chemotherapy is unknown. STUDY DESIGN: The Cancer and Pregnancy Registry, established in 1997, follows women diagnosed with cancer during pregnancy and continues annually for both mother and child after delivery. Children with hearing loss were identified in relation to maternal cancer type, stage and treatment during pregnancy. RESULTS: Four children were identified as having hearing loss, including sensorineural hearing loss (3) and enlarged vestibular aqueducts (2). Two have bilateral hearing aids. One child was a member of a twin gestation, and the other twin has normal hearing. Mean maternal age at diagnosis was 34.6 +/-SD 5.9 years. Mean gestational age (GA) at diagnosis was 15.7 weeks. Cancer types included: Ovarian (2), Chronic Leukemia (1), and Cervical (1) cancer. Three children were exposed to chemotherapy in utero, 1 to alpha interferon. Seventy five percent (3/4) of cases with hearing loss in childhood were exposed to a platinum agent in pregnancy. Regimens: Cisplatin/Paclitaxel(1), Etoposide/Cisplatin/Bleomycin(1), and Carboplatin/Paclitaxel(1). Mean GA at first treatment was 22.1+/-SD 4.8weeks. Mean number of treatment cycles in pregnancy was 3.6 +/-1. Mean GA at delivery was 35.7 +/-3.7 weeks. The mean birth weight was 2,554.6 +/-625.12 grams. 16 additional children were exposed to cisplatin and 7 to carboplatin in utero without hearing loss. There were no statistical differences in the cancer stage, maternal age at diagnosis, number of treatment cycles, GA at the first treatment, GA at birth, birthweight or use of postnatal antibiotics between the affected and unaffected groups. CONCLUSION: Approximately 15.7% of children exposed to Cisplatin and 12.5% exposed to Carboplatin in utero were diagnosed with hearing loss in early childhood.
882 Risk for aneuploidy in the structurally normal growth restricted fetus OBJECTIVE: To assess the frequency of chromosomal aneuploidy in the intrauterine growth restricted (IUGR) fetus without major structural anomalies. STUDY DESIGN: A retrospective analysis utilizing a reference lab database was performed for patients undergoing invasive prenatal testing between 2011 and 2017. Inclusion criteria included the documented indication for testing of IUGR. Women with major structural malformations noted on ultrasound were excluded from analysis. We analyzed the frequency of varying types of aneuploidy in our cohort, and performed a subanalysis comparing aneuploidy results for fetuses with ultrasonographic soft markers to those without soft markers. RESULTS: There were 1802 patients without major structural abnormalities having invasive diagnostic procedures with IUGR as the indication for testing. There were 152 (8.5%) chromosomally abnormal fetuses. Of the chromosomally abnormal fetuses, there were 72 cases of Trisomy 18 (47.3 %), 6 cases of Trisomy 13 (3.9 %), and 20 cases of Trisomy 21 (13.2%). Partial deletion and duplication syndromes accounted for 28 cases (18.4%), triploidy accounted for 21 cases (13.8%), and other rare anomalies constituted 5 cases (3.2%). When fetuses with ultrasonographic soft markers were excluded, there were 98/1595 (6.2%) chromosomally abnormal fetuses. There was a statistically significant higher proportion of chromosomally abnormal IUGR fetuses when ultrasonographic soft markers were present 54/207 (26.1%) when compared to the proportion of chromosomally abnormal IUGR fetuses without any soft markers 98/1595 (6.2%), p<0.00001. CONCLUSION: Fetuses with isolated IUGR and no major structural abnormalities have a significant risk of aneuploidy. Our data suggests that patients with isolated IUGR should be offered diagnostic testing for chromosomal assessment. Further prospective studies are needed to delineate the utility of chromosomal microarray, whole exome sequencing, and cfDNA in the assessment and etiopathogenesis of the fetus with isolated IUGR. 
